MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109

MBX Biosciences (MBX) announced the completion of enrollment in its Phase 2 Avail trial of MBX 2109, the Company’s parathyroid hormone peptide prodrug. Canvuparatide is designed to be long-acting and is in development for the treatment of chronic hypoparathyroidism. “Completion of enrollment in our Phase 2 trial in HP marks a significant milestone for MBX and brings us closer to our goal of delivering a long-acting PTH therapy designed to treat the underlying disease pathophysiology,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “We believe canvuparatide could transform the HP treatment landscape, potentially providing a more consistent therapeutic effect, while offering improved patient convenience and minimizing symptoms associated with large fluctuations in calcium. We look forward to reporting top-line data from the Phase 2 Avail trial in the third quarter of 2025.”